Press Releases + New

Date	Title and Summary	View
Toggle SummaryMay 08, 2014	Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders	View HTML Galectin Therapeutics to Hold Conference Call to Provide Corporate Update Following Company's Annual Meeting of Shareholders 13.5 KB
Toggle SummaryApr 23, 2014	Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis	View HTML Galectin Therapeutics Completes Enrollment of Second Cohort of Phase 1 Trial of GR-MD-02 for NASH (Fatty Liver Disease) With Advanced Fibrosis 19.5 KB
Toggle SummaryApr 17, 2014	Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis	View HTML Galectin Therapeutics Announces First Patient Dosed in Second Cohort of Phase 1 Trial of GR-MD-02 for NASH With Advanced Fibrosis 19.1 KB
Toggle SummaryMar 31, 2014	First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis	View HTML First Cohort Results in Galectin Therapeutics' Phase 1 Trial Reveal Biomarker Evidence of Therapeutic Effect on Fibrosis and Inflammation in NASH With Advanced Fibrosis 23.9 KB
Toggle SummaryMar 25, 2014	Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease Company to Hold Webcast and Conference Call on April 1 to Review Findings	View HTML Galectin Therapeutics to Announce Results From First Cohort of Phase 1 Clinical Trial in Fatty Liver Disease 15.9 KB
Toggle SummaryMar 21, 2014	Galectin Therapeutics Reports 2013 Financial Results	View HTML Galectin Therapeutics Reports 2013 Financial Results 29 KB
Toggle SummaryFeb 26, 2014	Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease	View HTML Galectin Therapeutics Secures U.S. Patent for its Proprietary Galectin Inhibitor GR-MD-02 in Fatty Liver Disease 17.2 KB
Toggle SummaryFeb 24, 2014	Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop	View HTML Galectin Therapeutics Presents at JMP Securities' Nonalcoholic Steatohepatitis (NASH) Workshop 13.1 KB
Toggle SummaryFeb 13, 2014	Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference Noteworthy Panel of Oncology Experts Focuses on Immunotherapy as an Important Cancer Treatment Modality	View HTML Galectin Therapeutics CEO Serves on Cancer Immunotherapy Panel at BIO CEO & Investor Conference 18.8 KB
Toggle SummaryFeb 05, 2014	Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference	View HTML Galectin Therapeutics to Present at 16th Annual BIO CEO & Investor Conference 13.1 KB